Compare EDBL & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDBL | LNAI |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 2.1M |
| IPO Year | 2021 | 2014 |
| Metric | EDBL | LNAI |
|---|---|---|
| Price | $0.83 | $0.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 145.8K | 99.9K |
| Earning Date | 11-13-2026 | 10-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.85 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,810,000.00 | $51,992.00 |
| Revenue This Year | $24.00 | N/A |
| Revenue Next Year | $282.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.08 | $0.22 |
| 52 Week High | $17.30 | $5.02 |
| Indicator | EDBL | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 20.26 | 14.77 |
| Support Level | $0.44 | $0.22 |
| Resistance Level | $1.20 | $1.65 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 10.81 | 4.49 |
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces. Company provides two principal product segments: (i) fresh produce, including cut herbs, hydroponic basil, potted herbs, and wheatgrass; and (ii) shelf-stable and refrigerated consumer packaged goods, including sports nutrition and nutraceuticals.
Lunai Bioworks Inc is an AI-driven biotechnology company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or lifelong cancer remission in some of the deadliest cancers. The Group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. Its reportable segments are BioSymetrics, which derives the maximum revenue, and RENB. Geographically, the Group operates in the United States and Canada.